Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: A decision analysis

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2267-2274

  Stiggelbout, A M ^e   Kiebert, G M ^a   De Haes, J C J M ^b   Keizer, H J ^a   Stoter, G ^c   De Wit, R ^c   Vermorken, J B ^d   Leer, J W H ^a   Kievit, J ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NONE

Author keywords

Adjuvant chemotherapy; Medical decision making; Patient preferences; Quality of life; Surveillance; Testicular cancer

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARTICLE; DECISION MAKING; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; TESTIS CANCER; TREATMENT INDICATION;

ATTITUDE OF HEALTH PERSONNEL; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; GERMINOMA; HUMANS; LONG-TERM CARE; MALE; PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TESTICULAR NEOPLASMS;

EID: 0030474301     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00279-1     Document Type: Article

References (34)

1. 1. Droz JP, van Oosterom AT. Treatment options in clinical stage I NSGCT of the testis: a wager on the future? A review. Eur J Cancer 1993, 29A, 1038-1044.
2. 2. Stephenson RA. Surveillance for clinical stage I nonseminomatous testis carcinoma: rationale and results. Urol Int 1991, 46, 290-293.
3. 3. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992, 10, 1762-1768.
4. 4. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987, ii, 294-298.
5. 5. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987, 316, 250-258.
6. 6. Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall Medical, 1991, 185-203.
7. 7. Sternberg CN. Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testicular tumors. Urol Clinics N Am 1993, 20, 93-109.
8. 8. Hendry WF. Abdominal surgery postchemotherapy in metastatic non-seminoma. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall Medical, 1991, 267-285.
9. 9. Einhorn LH. Salvage therapy for germ cell tumors. Semin Oncol 1994, 21(Suppl. 7), 47-51.
10. 10. Mead GM, Stenning SP, Parkinson MC, et al. The second Medical Research Council Study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 1992, 10, 85-94.
11. 11. Stiggelbout AM, Kiebert GM, Kievit J, et al. The "utility" of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol 1995, 48, 1207-1214.
12. 12. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Plan Sci 1976, 10, 129-136.
13. 13. Boyd NF, Sutherland HJ, Heasman KZ, et al. Whose utilities for decision analysis? Med Decision Making 1990, 10, 58-67.
14. 14. Cullen M. Management of stage I non-seminoma: surveillance and chemotherapy. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall Medical, 1991, 149-166.
15. 15. Till JE, Sutherland HJ, Meslin EM. Is there a role for preference assessments in research on quality of life in oncology? Quality Life Res 1992, 1, 31-40.
16. 16. Schmoll H-J. Management of early stages of testicular seminoma: the current status. Rec Res Cancer Res 1993, 126, 237-255.
17. 17. Bajorin DF, Bosl GJ. Continued refinement in the treatment of germ cell tumour patients. Eur J Cancer 1991, 27, 677-678.
18. 18. Hudes GR, Grana G, Deshields MS, et al. Genitourinary cancer. Cancer Chemother Biol Res Modif 1992, 13, 508-540.
19. 19. Steyerberg EW, Keizer HJ, Stoter G, et al. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 1994, 30A, 1231-1239.
20. 20. Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clinics N Am 1991, 18, 561-573.
21. 21. Bokemeyer C, Schmoll H-J. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995, 13, 283-292.
22. 22. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Höltl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996, 14, 441-448.
23. 23. Rørth M., Cullen MH, Horwich A, et al. Management of patients with non-seminomatous germ cell tumours stage I. In EORTG Genitourinary Group Monograph 7: Prostate Cancer and Testicular Cancer. New York, Witey-Liss, 1990, 295-303.
24. 24. Baniel J. Late relapse of testicular cancer. J Clin Oncol 1995, 13, 1170-1176.
25. 25. Lowe BA. Surveillance vs. nerve-sparing retroperitoneal lymphadenectomy in stage I nonseminomatous germ-cell tumors. Urol Clin N Am 1993, 20, 75-83.
26. 26. Oliver F, Mead G. Testicular cancer. Curr Opin Oncol 1993, 5, 559-567.
27. 27. Sheinfeld J. Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology 1994, 44, 2-14.
28. 28. Munro AJ, Warde PR. The use of a markov process to simulate and assess follow-up policies for patients with malignant disease: surveillance for stage I nonseminomatous tumors of the testis. Med Decis Making 1991, 11, 131-139.
29. 29. Nichols CR, Roth BJ. Management of metastatic non-seminoma: development of effective chemotherapy. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall Medical, 1991, 185-203.
30. 30. Goldstraw P. Thoracotomy postchemotherapy in non-seminoma patients. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall Medical, 1991, 287-296.
31. 31. Bajorin DF, Herr H, Motzer RJ, et al. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol 1992, 19, 148-158.
32. 32. Scher HI, Bajorin DF, Motzer RJ, et al. The evolving role of chemotherapy of germ cell tumors. Rec Res Cancer Res 1993, 126, 257-272.
33. 33. Peckham M. Testicular cancer. Acta Oncol 1988, 27, 439-452.
34. 34. Loehrer PJ. Salvage therapy and autologous bone marrow transplantation. In Horwich A, ed. Testicular Cancer. Investigation and Management. London, Chapman & Hall Medical, 1991, 257-266.